ABSTRACT
INTRODUCTION
Neuroblastoma (NB) is a heterogeneous childhood malignancy from embryonic origin arising from neural crest progenitor cells (NCPC) of the sympathoadrenal lineage [1] . Neural crest (NC) is a transient highly migratory population of neuroectodermal pluripotent stem cells in vertebrate embryo. NC cells from the trunk migrate and differentiate to give rise to glia, neurons of the dorsal root ganglia, Schwann cells, melanocytes, and adrenal medulla [2] [3] [4] . NB is believed to originate from a subset of these migratory NC derivatives committed to the sympathoadrenal lineage, which differentiate into adrenal chromaffin cells or sympathetic ganglia [1, 4] .
The anaplastic lymphoma kinase (ALK) gene belongs to the insulin receptor superfamily of receptor tyrosine kinase (RTK). ALK has been recently extensively studied as a candidate in the development of new targeted treatments for progressive and resistant NB. ALK is expressed in the developing central and peripheral nervous system during embryogenesis [5] , and in the developing sympathoadrenal lineage of the NC, where its signaling may regulate the balance between cell proliferation and differentiation [1, 6, 7] . ALK physiological role in the normal development of the nervous system is not yet fully understood, but ALK having a role in neurogenesis control was demonstrated in Drosophila, zebrafish, and chicken [6, 8, 9] .
ALK mutations were described in ~10 % of NB cases, copy number gain in ~15%, and ALK amplification in 2-4 % of NB [1, [10] [11] [12] [13] [14] [15] [16] . Furthermore, overexpression of ALK-wt or mutated receptors was detected in the majority of NB, and was shown to be associated with poor clinical outcome [17, 18] . The two most frequent mutations F1174L (only present in sporadic NB) and R1275Q (in sporadic and familial NB) correspond to 34.7% and 49% of mutated ALK, respectively [10, 15, 19] . Both mutations lead to ALK constitutive activation by autophosphorylation, although ALK-F1174L displays a higher degree of phosphorylation, and an increased tumorigenic potential compared to other ALK mutations [10, 13, [20] [21] [22] 26] . Both activating mutations, ALK-F1174L and ALK-R1275Q, were also shown to contribute to NB tumorigenesis in transgenic and knock-in (KI) animal models, as well as to cooperate with MYCN in the oncogenic process [23] [24] [25] [26] . In patient, although association of ALK-F1174 hotspot mutations with MYCN amplification is still under debate [10, 11] , co-occurrence of both genetic alterations lead to very poor outcome compared to single defect.
To date, the role of activating ALK mutations or ALK-wt overexpression in NB tumor initiation and progression remains unclear. Indeed, although germline activating ALK mutations occur in 80% of familial NB, they display incomplete penetrance suggesting that additional genetic alterations may be required for NB initiation [15, 16, 27] . Moreover, ALK-F1174L expression, in mouse and zebrafish transgenic NB models, as well as in KI model, was not sufficient to initiate NB tumor formation in absence of MYCN co-expression or additional genetic alterations syntenic to that commonly found in human NB [23] [24] [25] 26] . This suggests that ALK-F1174L, similarly to germline ALK mutations, required secondary hits to drive NB formation [23] .
In this study, we investigated the ability of ALK-wt, and the most common activating mutations, ALK-F1174L and ALK-R1275Q, to initiate tumor formation in NCPC, and we compared their in vivo oncogenic potential. In this aim, two murine NCPC models were selected, the MONC-1 cell line immortalized with v-Myc [28] , and the JoMa1 cell line expressing a Tamoxifen-inducible Myc-ER T [29] , allowing evaluation of ALK-wt and variant functions in presence or absence of exogenous Myc activity. Stable expression of ALK-wt or gain-of-function mutants in NCPC were sufficient to induce formation of highly aggressive and undifferentiated tumors, but not to drive NB tumor progression. Moreover, Myc endogenous expression was strongly upregulated in orthotopic JoMa1-ALK tumors or their derived cell lines as a result of ALK activation, and both ALK and Myc activities were required to maintain in vitro tumorigenic capacities of tumorderived cell lines. These data strongly support a role for ALK-wt, in addition to ALK-F1174L and ALK-R1275Q, to confer in vitro and in vivo tumorigenic properties on NCPC.
RESULTS

ALK-F1174L expression in murine NCPC MONC-1 impairs differentiation of NC cellderived tumors.
To investigate the oncogenic potential of ALK-F1174L mutation in NCPC, human ALK-F1174L was overexpressed in the murine NCP cell line, MONC-1, previously immortalized by stable v-Myc expression [28] ( Figure 1A ). Transduced MONC-1 cells conserved their NCPC phenotype, as the NC stem cell (NCSC) markers, except Sox10, were still expressed, while glial or neuronal differentiation markers were not detected (Supplementary Figure 1A) . The tumorigenic potential of MONC-1-ALK-F1174L or parental MONC-1 cells was analyzed in vivo by orthotopic implantation into nude mice adrenal glands (AG). Interestingly, mice implanted with MONC-1-ALK-F1174L cells developed highly aggressive tumors in all mice (10/10, 100%) within three weeks, while mice engrafted with parental MONC-1 cells developed tumors in AG with a significantly longer latency (7/9, 78%) ( Figure 1B ). MONC-1-ALK-F1174L-derived tumors strongly expressed human ALK mRNA and protein as expected, but not murine Alk (Supplementary Figure 1B) . Thus, ALK-F1174L strongly accelerated MONC-1 cellderived tumor growth.
All mice implanted with MONC-1-ALK-F1174L cells developed highly malignant undifferentiated tumors, as they strongly expressed the mesechymal/ stem marker CD44 and the neural stem/progenitor cell marker nestin, but did not stain for the neuronal marker Ncam1, the adrenergic differentiation marker tyrosine hydroxylase (Th), and the sympathoadrenal marker Phox2b, recently demonstrated as a highly specific marker of undifferentiated NB [30] (Figure 1C) . In contrast, MONC-1 cells gave rise to various tumor types, as 3/7 mice developed osteosarcoma with chondrosarcoma components ( Figure 1D) Figure 1F ). The three MONC-1-derived NB tumors displayed features of unfavorable NB as seen in patients, such as stroma poor and high MKI (data not shown). These NB tumors expressed reduced levels of CD44, but increased levels of Ncam1, compared to undifferentiated tumors derived either from MONC-1 or MONC-1-ALK-F1174L cells ( Figure 1C , E, and F 
JoMa1 cells expressing ALK-wt, ALK-F1174L, or ALK-R1275Q are tumorigenic in vivo.
We next addressed the oncogenic potential of ALKwt and ALK-R1275Q mutation, as compared to ALK-F1174L variant, in NCPC in absence of v-Myc oncogene expression. For this purpose we used the murine NCP cell line, JoMa1, expressing Tamoxifen (4-OHT)-inducible Myc-ER T [29] . Human ALK-wt, ALK-F1174L, and ALK-R1275Q variants were stably overexpressed in JoMa1 cells, while endogenous murine Alk was undetectable in these cells (Figure 2A ). NCPC phenotype of transduced JoMa1 cells was not affected by retroviral infections and ALK expression. Indeed, except for Sox10 expression which was undetectable in JoMa1-ALK-R1275Q cells, transduced cells still expressed the NCSC markers Ngfr, Sox9, Snai1, and Snai2, while glial, or neuronal differentiation markers were not detected ( Figure 2B ). Sustained ALK activation was detected by immunoblotting in JoMa1-ALK expressing cells ( Figure 2C ).
The in vivo tumorigenic potential of JoMa1-ALK-F1174L, -ALK-R1275Q, and -ALK-wt cells was then assessed after subcutaneous engraftment in absence of 4-OHT, thus without Myc-ER T activation. Interestingly, JoMa1-ALK-wt cells were able to drive tumor formation, likewise JoMa1-ALK-R1275Q, and JoMa1-ALK-F1174L cells, while JoMa1-Migr and JoMa1 control cells did not induce tumor development ( Figure 2D ). ALK-F1174L conferred an enhanced tumorigenic potential to JoMa1 cells when compared to ALK-R1275Q and ALK-wt ( Figure 2D ). Human exogenous ALK expression in JoMa1-derived subcutaneous tumors was confirmed by IHC and RT-PCR analyses, while murine Alk mRNA was undetected ( Figure 2E and Supplementary Figure 2) . Thus, in absence of any exogenous Myc activation, ALKwt or ALK activating mutations displayed transforming 
JoMa1-ALK-wt, -ALK-F1174L, and -ALK-R1275Q cells generate undifferentiated NC cellderived tumors in vivo upregulating NCSC or SC associated markers
Orthotopic implantations were then performed in order to faithfully reproduce NB tumor microenvironment. As observed in subcutaneous implantations, JoMa1-ALK expressing cells rapidly induced tumor formation, and mice engrafted with JoMa1-ALK-F1174L cells developed tumors in AG much faster than JoMa1-ALK-R1275Q and JoMa1-ALK-wt bearing mice (p<0.02), while no tumor was found in mice implanted with JoMa1 or JoMa1-Migr control cells ( Figure 3A) . Exogenous ALK expression in orthotopic tumors was confirmed by RT-PCR, WB and IHC, while murine Alk was undetected ( Figure 3B , and Supplementary Figure 3) . Ki67 labeling revealed an enhanced proliferation index in JoMa1-ALK-F1174L-derived tumors (48%) compared to JoMa1-ALK-R1275Q-(40%), and JoMa1-ALK-wt-derived tumors (38%) (Figure  3b ), suggesting that the accelerated tumor growth of JoMa1-ALK-F1174L tumors may partly result from their increased proliferation capacity.
Subcutaneous and orthotopic JoMa1-ALK-derived tumors correspond to highly malignant undifferentiated tumors ( Figure 2E , and 3B), Phox2b -/Th -, but strongly expressing CD44, nestin, and weakly Ncam1 ( Figure 3C ). Tumors histologically close to NB, such as Ewing tumors, melanoma, or lymphoma were excluded, as their specific markers (CD99, Tyr, and Ptprc (CD45), respectively) were not detected ( Figure 3C ). Hence, JoMa1-ALK-wt, -F1174L, -R1275Q cells, similarly to MONC-1-ALK-F1174L cells, gave rise to undifferentiated NC cell-derived tumors.
Activation well as to transcriptome of JoMa1 cells and cell lines established from JoMa1-NMYC-derived tumors (mTu3-6) described by Schulte et al. [22] , using the same Affymetrix arrays. Clustering results revealed that the three groups of JoMa1-ALK (F1174L, R1275Q, and wt) orthotopic tumors clustered together and close to JoMa1 and JoMa1-NMYC derived tumors cell lines, as well as to adrenal glands, while NB derived from murine transgenic models were much more distant (Supplementary Figure  5) . This confirms that our orthotopic JoMa1-ALK-derived tumors were significantly different from murine NB models. This also indicates that variations found between JoMa1-ALK tumors and NB transgenic models did not result from differences between experimental procedures, as all JoMa1 samples (ours and those of Schulte et al.) clustered together (Supplementary Figure 5) . Analyses of differentially regulated genes (FC>3 and p<0.05) revealed 1634 upregulated, and 1493 downregulated genes in orthotopic JoMa1-ALK tumors compared to transgenic NB tumors. Interestingly, various NCSC or SC associated markers, such as Myc, Sox2, Sox9, Notch1, Notch2, Snai2, Bmp1/2, Twist1/2, Hmga2, nestin, and vimentin were identified among the upregulated genes (Table 1) , while sympathoadrenal lineage markers (Phox2a, Phox2b, Gata2, Gata3, Th, and Dbh), neuroendocrine markers (Chromogranin A, synaptophysin), neuronal markers ( Figure  3D ). These results confirm that in our NCPC model, ALKwt or activating ALK variants drive the formation of highly undifferentiated NC cell-derived tumors, and may even impair NB tumor differentiation. 
Tumor-derived
ALK mediates Myc upregulation in JoMa1-ALK tumors and tumor-derived cell lines, and both oncogenes cooperate in the oncogenic process.
Myc was found to be overexpressed in JoMa1-derived tumors compared to NB transgenic models, while Mycn was downregulated (Table 1) . To validate these data, Myc and Mycn mRNA expression levels were measured in JoMa1-ALK tumors and in their respective parental or tumor-derived cell lines. Myc was upregulated in transduced JoMa1-ALK-F1174L and -ALK-R1275Q cells relative to JoMa1-Migr control cells (Supplementary Figure 6A) . In addition, Myc mRNA expression level was increased in orthotopic and subcutaneous tumors compared to their respective parental JoMa1-ALK cells ( Figure 5A , and Supplementary Figure 6B) . Moreover, Myc was also significantly upregulated in t.d.cell lines as compared to their tumors of origin ( Figure 5B ). Furthermore, JoMa1-ALK-F1174L tumors, or t.d.JoMa1-ALK-F1174L cells, expressed significantly higher amounts of Myc mRNA compared to JoMa1-ALK-R1275Q-and JoMa1-ALK-wtderived tumors, or -associated t.d.cell lines, respectively ( Figure 5A , 5B, and Supplementary Figure 6B) . Finally, qPCR analyses confirmed the particularly weak Mycn mRNA expression levels in JoMa1-ALK orthotopic tumors and t.d.cell lines relative to Myc levels ( Figure 5C and B, see the different scales). However, Mycn mRNA expression was superior in JoMa1-ALK-F1174L tumors relative to JoMa1-ALK-R and JoMa1-ALK-wt tumors ( Figure 5C ). Altogether, these results suggest that Myc, rather than Mycn, may have an essential role in the tumorigenesis of ALK-expressing JoMa1 cells in vivo.
To further investigate whether Myc upregulation observed in t.d.cells was dependent on ALK activity, tumor-derived and parental JoMa1 cells were treated with the ALK inhibitor TAE684 for 24h. Myc mRNA expression was strongly downregulated upon TAE684 treatment ( Figure 5D , and data not shown for t.d.JoMa1-ALK-R and -ALK-wt cells). Interestingly, Mycn mRNA expression levels were inversely correlated to that of Myc, as Mycn was strongly upregulated in presence of TAE684, even if the Mycn/β-actin ratio remained extremely low compared to that of Myc ( Figure 5D ).
To analyze whether Myc upregulation participated to the increased tumorigenicity of t. 
DISCUSSION
The role of ALK-wt, ALK-F1174L and ALK-R1245Q in NB tumor initiation was investigated in two NCPC models, MONC-1 and JoMa1. We have demonstrated by orthotopic implantations in mice that parental MONC-1 cells produced diverse tumor types, such as undifferentiated NB, osteo-chondrosarcoma, and undifferentiated tumors, recapitulating the pluripotency of MONC-1 NCPC. Interestingly, ALK-F1174L expression in MONC-1 cells not only strongly accelerated tumor growth, but also affected their differentiation capacity. Indeed, MONC-1-ALK-F1174L cells only developed highly malignant undifferentiated tumors expressing high levels of the neural stem/progenitor cell marker nestin. Similarly, we provide the first demonstration that even in absence of exogenous Myc-ER T activity, ALK-wt, ALK-F1174L, or ALK-R1275Q expression in NCPC JoMa1 are sufficient to initiate highly aggressive, undifferentiated tumor formation, although not to drive NB progression. We have shown that MONC-1-ALK-F1174L-and JoMa1-ALK-derived tumors were nestin + and Phox2b -. Interestingly, hyperplastic lesions observed in early postnatal sympathetic ganglia derived from TH-MYCN NB mice models contained nestin + /Phox2b -cells. These cells were proposed to "represent a population of malignant sympathetic neural crest or early progenitor cells that give rise to Phox2b positive tumor cells comprising the bulk of NB tumors" [31, 32] . Thus, ALK expressing MONC-1-and JoMa1-derived tumors may correspond to such malignant NCPC populations.
Comparison of gene expression profiles between orthotopic JoMa1-ALK-derived tumors and NB transgenic mouse models of Heukamp et al. [23] revealed a strong upregulation of SC-or NCSC-associated markers, and a significant downregulation of differentiation markers related to neuronal or sympathoadrenal lineage in JoMa1-ALK-derived tumors. Thus, in our NCPC models, ALK expression in MONC-1 or JoMa1 cells appeared to maintain tumor cells in an undifferentiated state. The high Myc/Mycn ratio detected in our orthotopic tumors may partly explain their stem-like phenotype, as Myc is one of the few genes needed to induce pluripotent stem cell reprogramming [33] . Although produced in the same JoMa1 model, our results differ from Schulte et al. report, which show only a very weak tumorigenic and NB-inducing potential of JoMa1-ALK-F1174L cells after subcutaneous injection [22] . The selection of clones in Schulte study and variations in ALK-F1174L expression levels in JoMa1 cells are elements that could explain the discrepancies between both studies.
Understanding of mechanisms responsible for ALKmediated inhibition of NCPC differentiation will require further investigations. NB tumors expressing activated ALK derived from MYCN/KI ALK mice displayed a more differentiated phenotype as compared to MYCN tumors derived from TH-MYCN mice [26] . ALK was also shown to induce differentiation of PC12 cells by inducing neurite outgrowth [34] . However, membrane attachment of ALKtyrosine kinase domain was shown to be crucial for the control of neurite outgrowth and proliferation arrest, while cytoplasmic localization promoted cell proliferation [34] . Thus, ALK cellular localization may play a role in the switch between proliferation and differentiation. It should be noted that ALK localization in MONC-1-and JoMa1-ALK tumors was mostly cytoplasmic. Interestingly, ALK expression was recently shown to be associated with less differentiated neuroblastic tumors, as the frequency of ALK positivity in NB was significantly higher than in ganglioneuroblastoma, and in ganglioneuroma [35, 36] .
Observations that frequent ALK-wt overexpression in NB primary tumors was associated with poor clinical outcome, similarly to activating ALK mutations [10, 17, 18, 37] , suggested that ALK-wt overexpression may be involved in NB oncogenesis and progression. We demonstrate here for the first time that ALK-wt expression in NCPC JoMa1 can drive malignant tumor formation in nude mice. Until this study, ALK-wt transforming capacity could not be demonstrated neither in clonogenic assays nor upon subcutaneous implantations [13, 14, 38, 39] . Also, ALK-wt expression was unable to cooperate with MYCN in inducing NB formation in a zebrafish NB model [25] . These negative results may be explained by ALK-wt protein expression levels, which probably did not reach the critical threshold necessary for ALK-wt oncogenic autoactivation [40] , while here we were able to detect a weak constitutive ALK phosphorylation in transduced JoMa1-ALK-wt cells.
The capacity of activating ALK mutations or ALK-wt overexpression to initiate tumor formation and progression may be dependent on their expression levels, as discussed above, as well as on their temporal expression during sympathetic neuronal development and differentiation. The production of a Tamoxifendependent Cre model allowing ALK activation at different development time points, as suggested [23] , could help to determine whether a specific development period exists for NB tumor initiation and progression. Here, ALK was expressed in NCPC, which represent a very early stage of NC cell differentiation, as compared to ALK expression driven by Th or Dbh promoters in NB transgenic models. Indeed, Th and Dbh are expressed later in more differentiated cells of the sympathoadrenal lineage during noradrenergic induction of sympathetic neurons [1, 4] . The bona fide model to study the exact role of ALK mutations in NB tumor initiation and progression is the generation of ALK KI mutants, as recently described by JanoueixLerosey et al. [26] . In this study, the KI of the murine equivalents (ALK-F1178L and R1279Q in mice) of the two most frequent ALK activating mutations in patient were generated. ALK KI mice displayed in an enlargement in sympathetic ganglion resulting from enhanced proliferation of sympathetic neuroblasts [26] . However, expression of activating mutants did not generate tumors in mice in absence of MYCN expression, confirming that activated Alk was not sufficient to drive neuroblastic tumors [26] . So, our NCPC JoMa1 model revealed the strong tumor-initiating capacity of ALK-wt and activating mutants, in contrast to NB murine models. Indeed, in zebrafish and murine NB transgenic models, ALK-F1174L expression driven by Dbh or Th promoter, as well as activated ALK KI mutants, did not allowed to confer a fully transformed phenotype to NC derived cells, and thus to induce tumor formation, while co-expression of MYCN was required for NB development [24, 25, 26] . Also, ALK-F1174L required additional hits to drive NB development in the conditional actin-ALKF
1174L
;DBHHiCre transgenic mouse model of Heukamp et al., as NB tumors occurred only in presence of additional genetic alterations [23] . Thus, ALK was not sufficient to drive NB formation both in NB murine models, and in our NCPC model.
We also confirmed the previously described remarkable tumorigenic potential of ALK-F1174L mutation [10, 13, [20] [21] [22] 38] [21] , and cooperate with MYCN in NB tumorigenesis [21, [23] [24] [25] , but they may also upregulate and cooperate with Myc, as observed in murine NCPC. Interestingly, the tumorigenic potential of t.d.-JoMa1-ALK expressing cells was strongly dependent on both ALK and Myc activities, as ALK or Myc inhibitor completely impaired their in vitro clonogenic potentials. Therefore, our NCPC models allowed us to demonstrate the role of ALK-wt and the most frequent activating ALK mutations in NCPC in tumor initiation and in differentiation control. These models may also be valuable in the further identification of ALK-mediated mechanisms in oncogenesis.
MATERIALS AND METHODS
Culture of MONC-1 and JoMa1 cells
MONC-1 and JoMa1 cells were maintained in an undifferentiated state using the NC culture medium (NCCmedium [29] ), supporting NCPC proliferation, composed of Dulbecco's Modified Eagle Medium (DMEM) F-12 (Invitrogen), 1% N2-Supplement (Invitrogen), 2% B27-Supplement (Invitrogen), 10 ng/ml EGF (R&D), 4 ng/ ml FGFβ (PeproTech), 1% Penicillin-Streptomycin (Invitrogen), and 10% Chicken-Embryo-Extract [43] . Cells were cultivated in fibronectine coated dishes (1mg/ ml, Sigma-Aldrich). For Myc-ER T activation, 200 nM 4-OHT (Sigma-Aldrich) was added to NCC-medium.
Retroviral infections
ALK cDNA XhoI-EcoRI fragments, isolated from ALK-wt-, ALK-F1174L-, and ALK-R1275Q-pcDNA3 constructs [44] were introduced into XhoI-EcoRI sites of the biscistronic retroviral vector pMigr1 encoding for eGFP [45] . All ALK-expressing vectors were verified by DNA sequencing. Retroviral infection were performed as described previously [46] , and GFP + cells sorted by FACS Aria Cell Sorter (Becton Dickinson). After expansion, transduced cells were frozen, and in vitro or in vivo assay were performed with only early cell passages.
RNA preparation and RT-PCR
Total RNA from cell lines and tumors were extracted using RNeasy or miRNeasy Mini kits (Qiagen), respectively. CDNA were prepared as described earlier [47] . PCR using GoTaq Hot Start Kit (Promega) were performed with following primers: Ngfr-for 5'-GAATGCGAGGAGATCCCTGG-3', Ngrf-rev 5'-GGAGCAATAGACAGGAATGAGG-3', Snai1-for 5'-CACCCATACAGGTGAGAAGC-3', Snai1-rev 5'-TGTCCTGGATGACAGAACCA-3', Nefh-for 5'-GCAGCCAAAGTGAACACAGA-3, Nefh-rev 5'-CTGAATAGCGTCCTGGTAGG-3', Mash1-for 5'-TTGAACTCTATGGCGGGTTC-3', Mash1-rev 5'-GCCATCCTGCTTCCAAAGTC-3', human ALK-for 5'-TGTTGCCTCTCCTCGATGTG-3', human ALKrev TGTCTTCTCCGCTAATGGTG-3', murine Alk-for 5'-TGCCAGAAGTGTGTTCAGAAC-3', murine Alk-rev 5'-CCCTTCCATGAAGGCTTCAG-3'. Primers for Snai2, Sox9, Sox10, Gfap, Gapdh were described [29] . Cycling reactions were 2min at 95°C followed by 35 cycles of 30s at 95°C, 30s at 60 to 65°C and 30s at 72°C, followed by 5min at 72°C.
Real-Time qPCR
Expression levels of Myc, Mycn, and β-actin were assessed by semi-quantitative real-time qPCR as described [47] with the QuantiFast SYBR® green kit (Qiagen) and primers specific for murine Myc, Mycn, and β-actin (QuantiTect primer assay, Qiagen). Cycling conditions were 5min at 95°C, 40 cycles of 10s at 95°C, 20s at 60°C, and 1s at 72°C. Ratio of Myc or Mycn to β-actin gene expression was evaluated using the ∆Ct method.
Immunoblotting
JoMa1 cells were lysed in 10 mM Tris-Hcl (pH 7.4), 150 mM NaCl, 5 mM EDTA, 25 mM β-glycerophosphate, 10% glycerol, 1% NP40, 0.25 % Na-deoxycholate, 20 mM NaF, 1 mM Na-pyrophosphate, 1 mM Na 3 VO 4 and 1x protease inhibitor. Cell lysates were sonicated three times for 10 sec, and centrifugated at 13'000 rpm at 4°C during 30 min. Phosphoproteins were detected using polyclonal rabbit antibodies specific for phospho-ALK (pTyr1604, AssayBioTech), phospho-AKT (Cell Signaling), phospho-STAT3 (Cell Signaling) or phospho-ERK (Cell Signaling). Membranes were stripped 10min at 50°C in 2% SDS, 65.5 mM Tris-HCL pH 6.8 and 100 mM β-mercaptoethanol, and total protein expressions were detected using polyclonal rabbit antibodies specific for ALK (Invitrogen), AKT (Cell Signaling), STAT3 (Cell Signaling), or ERK (Cell Signaling).
Methylcellulose clonogenic assay
JoMa1 cells (1.3*10
3 ) were grown in 500 µl semisolid medium [53% methylcellulose (Fluka, and prepared as in [48] ), 17% FCS (Sigma), 30% DMEM (Gibco), and Penicilin-Streptomycin] in PolyHema (poly-2-hydroxyethyl-methacrylate, 16 mg/ml in EtOH, Sigma)-coated 24-well culture plates, to prevent cell adhesion. Tamoxifen (200nM), TAE684 (1µM) or 10058-F4 (80µM) were added twice a week in 100μl DMEM complemented with 10% FCS and Penicillin-Streptomycin. After 2 weeks, colonies were counted using an optic microscope, stained with a mix of 50% MTS/PMS (Promega) and 50% DMEM (Gibco) during 2 hours, and pictures were taken with AlphaImager®.
In vivo studies
All animal experiments were carried out with female, athymic Swiss nude mice (BALB/C nu/nu), 4-6 weeks of age purchased from Charles River in accordance to the European Community guidelines (directive no. 86/609/CEE) as described [49, 50] . In subcutaneous model, 5x10 5 cells were injected in both flanks of mice (3 per group). In orthotopic model, 10, or 7 mice per groups were injected in left AG with 10 5 MONC-1 cells, or 1.5x10 5 JoMa1 cells, respectively, resuspended in 10 μl of PBS. Abdominal incisions were closed with skin clips.
Tumor take and growth were followed up using calipers twice a week for subcutaneous injections or by ultrasound every 3, 7, or 14 days according to tumor progression. Subcutaneous or orthotopic tumor volumes were calculated using the formula (length×width 2 )/2, or 4/3×π×(depth×sagittal×transversal)/6 formula, respectively. Mice with tumor volumes greater than ~1000 mm 3 , or ~800 mm 3 were sacrificed for subcutaneous, or orthotopic injections, respectively. Every tumor was split into pieces for paraffin-embedded tissue formation, RNA or protein extraction, or cell dissociation.
Tumor dissociation and establishment of tumorderived cell lines
Cells were dissociated from orthotopic tumors as described earlier [51] and propagated like parental cells. Tumor-derived cell purity was analyzed after 2 weeks by flow cytometry for GFP expression.
Immunohistochemistry
All immuno-labeling were performed by the Lausanne Mouse Pathology Facility. Hematoxylin and eosin (H&E) staining was performed on all subcutaneous and orthotopic tumors. Immunohistochemistry (IHC) was performed using mouse monoclonal Ab anti-TH (MAB318, Millipore), rabbit polyclonal Ab anti-ALK (51-3900, Invitrogen), anti-Tyr (a gift from Bhushan Sarode, EPFL), anti-CD99 (Orb13719, Biorbyt), anti-Ncam1 (14255-1-AP, Proteintech), rat monoclonal Ab anti-CD44 (550538, BD Pharmingen), anti-Ptprc (CD45) (550539, BD Pharmingen), anti-nestin (MAB353, Millipore), antiKi67 (M7249, DAKO), anti-Phox2b (H-20, Santa Cruz Biotechnology).
Ki67 proliferation index was determined by analyzing 5 fields imaged at 40x magnification per tumor section in 4 different tumors from each group. Sections were imaged using a Zeiss Axio LabA1 microscope and Axiovision Rel. 4.5 imaging software.
Microarray analyses
CDNA, prepared from total RNA of orthotopic tumors, were hybridized to the Affimetrix GeneChip® Murine 430.2 oligonucleotide Array according to manufacturer's instructions. Arrays were normalized by the GCRMA procedure using Brainarray annotations [52] .
